12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Company News  |  Deals

Axxam, Polyphor deal

The companies partnered to discover and develop therapeutics that modulate glucagon-like peptide-1 receptor ( GLP-1R; GLP1R) to treat Type II...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >